Latest / The Productivity Podcast with Fexingo: Output, Efficiency, and Long-Term Economic Growth / Why Portugal's Decriminalization Boosted Economic Productivity
Transcript
- Lucas: Portugal decriminalized all drugs in 2001. And at the time, plenty of economists and policymakers predicted disaster — more addiction, more chaos, a drag on the economy. But what actually happened is one of the most underappreciated productivity stories of the last two decades. Luna: Underappreciated is right. I remember seeing a stat that Portugal's drug-related deaths dropped to something like three per million adults, while the EU average is over twenty. But I've never thought about the productivity angle directly. Lucas: That's exactly where the numbers get interesting. Let's start with incarceration costs. Before decriminalization, Portugal's prison population was rising fast — a lot of people locked up for possession. Incarceration is incredibly expensive, and it removes people from the labor force entirely. After decriminalization, the prison population dropped by about 20 percent over a decade. Luna: So that's a double benefit — you're spending less on prisons and you've got more people who can work. Lucas: Exactly. And it's not just about the people who would have been incarcerated. There's also the stigma effect. When drug use is a criminal offense, even people who never serve time can have a criminal record that makes it harder to get a job. Portugal eliminated that barrier for simple possession. Researchers at the University of Lisbon estimated that the reform increased labor force participation by roughly two to three percent among the most affected demographics. Luna: That's a meaningful bump for a policy change that costs almost nothing to implement. What about health outcomes — do those feed into productivity too? Lucas: Absolutely. Chronic drug use obviously harms health, but the criminal-justice approach actually makes things worse — people avoid treatment, needle sharing increases, infectious diseases spread. Portugal redirected funding from policing to treatment and harm reduction. The result: a 40 percent drop in drug-related deaths, a 17 percent reduction in hepatitis and HIV rates. Healthier workers are more productive, miss fewer days, and are less likely to drop out of the labor force entirely. Luna: So you've got a healthier, larger workforce. Have economists actually tried to quantify the GDP impact? Lucas: A few studies have. The most cited one, from the Portuguese Economics Ministry, estimated that the reform added roughly 0.5 percent to annual GDP growth in the first decade, largely through reduced absenteeism and higher participation. That might not sound huge, but compounded over twenty years, that's a significant cumulative gain. Luna: And this is the kind of policy that, if it were a corporate strategy, every CEO would want to replicate. But politically, it's still a third rail in a lot of countries. Lucas: That's the fascinating tension. The data is pretty clear — Portugal didn't see a spike in overall drug use, and the economic benefits are measurable. But the moral framing around drugs in places like the US and UK still dominates policy. Let's compare Portugal to the Czech Republic, which decriminalized in 2010 with similar but not identical results. Luna: What did the Czechs do differently? Lucas: The Czech Republic kept some penalties for possession of larger amounts and focused more on treatment rather than full decriminalization. Their incarceration drop was smaller — about 12 percent — and their labor force participation gains were around 1.5 percent. Still positive, but less dramatic. Switzerland went even further — they actually regulated and taxed cannabis and heroin-assisted treatment. Their productivity gains came more from tax revenue and reduced black-market costs. Luna: So there's a spectrum. But Portugal's version seems to have the strongest economic case because it's the simplest — just remove the criminal penalty for personal use. Lucas: Right. And the cost savings are huge. Portugal saved about 50 million euros a year in direct law enforcement and prison costs, which it reinvested in health services. That's a classic productivity play — reallocate resources from low-value to high-value activities. Luna: I want to ask about something that often comes up in these debates: the concern that decriminalization sends a signal that drug use is acceptable, which could increase use and harm productivity. But the data from Portugal doesn't show that, right? Lucas: It doesn't. Lifetime drug use rates in Portugal actually fell slightly after decriminalization, and problematic use — defined as daily or near-daily use of hard drugs — remained stable. The big change was that people who did use were more likely to seek treatment. And treatment is far cheaper than incarceration. The cost-benefit analysis is overwhelmingly positive. Luna: So why haven't more countries followed Portugal's lead? Especially when the economic argument is this strong. Lucas: Partly political ideology — drug policy is often driven by moral values rather than evidence. And partly institutional inertia. The US, for example, has a massive prison-industrial complex that actively lobbies against decarceration. But there are signs of movement. Several US states have decriminalized or legalized cannabis, and there's growing bipartisan interest in harm reduction. The Biden administration expanded access to medication-assisted treatment. But we're still far from a Portugal-style approach. Luna: Let's talk about the UK, which has actually tightened some drug laws recently. Is there any economic analysis on what that costs? Lucas: A 2023 report from the UK's Office for Health Economics estimated that the current enforcement-heavy approach costs the UK economy about 1.5 billion pounds annually in direct criminal justice costs and lost productivity. That's roughly 0.1 percent of GDP. Not enormous, but significant for a policy with no proven public health benefit. Luna: It's always surprising to me that something that seems so intuitively counterproductive — locking people up for addiction — persists when the numbers are this clear. But I guess that's why economics is sometimes called the dismal science. The rational answer isn't always the political one. Lucas: Exactly. And that's a broader lesson for productivity. Sometimes the biggest gains come not from a new technology or management technique, but from removing a counterproductive rule or policy that's been in place for decades. Portugal showed that decriminalization wasn't just a public health win — it was an economic productivity win too. Luna: If walking through the economy with us has made something click, whether it's this episode or a previous one, we've got a small ask. Listener support is what keeps this show ad-free and independent. If today's conversation was worth a coffee to you, that's literally the link — buy me a coffee dot com slash fexingo. Lucas: Yeah, no pressure at all. It's just a way for people who find value here to chip in if it feels right. Every little bit helps us keep digging into these stories. Luna: So back to Portugal — what's the one thing you think a policymaker from another country should take away from this case? Lucas: That decriminalization is not a radical experiment anymore. It's a twenty-five-year-old policy with a strong track record. The productivity gains are real, measurable, and durable. And the cost of inaction — continuing to criminalize addiction — is higher than most people realize. Luna: I think that's a good place to leave it. Thanks Lucas. Lucas: Thanks Luna. Great conversation.